These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30950448)

  • 1. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
    Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
    Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classifying Glioma via Liquid Biopsy: Progress toward an Unmet Clinical Need.
    Abdullah KG
    Clin Cancer Res; 2024 Jul; 30(14):2860-2861. PubMed ID: 38652677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid cfDNA Sequencing for Classification of Central Nervous System Glioma.
    Iser F; Hinz F; Hoffmann DC; Grassl N; Güngoör C; Meyer J; Dörner L; Hofmann L; Kelbch V; Göbel K; Mahmutoglu MA; Vollmuth P; Patel A; Nguyen D; Kaulen LD; Mildenberger I; Sahm K; Maaß K; Pajtler KW; Shankar GM; Weiler M; Wildemann B; Winkler F; von Deimling A; Platten M; Wick W; Sahm F; Kessler T
    Clin Cancer Res; 2024 Jul; 30(14):2974-2985. PubMed ID: 38295147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
    Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
    Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
    Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
    Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
    Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and Correlation of Single and Concomitant
    Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
    Okamura R; Piccioni DE; Boichard A; Lee S; Jimenez RE; Sicklick JK; Kato S; Kurzrock R
    Int J Cancer; 2021 Jun; 148(11):2839-2847. PubMed ID: 33497479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
    Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
    J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
    Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
    Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy.
    Husain A; Mishra S; Hadi R; Sahu A; Kumari S; Rastogi M; Khurana R; Shukla S; Siddiqui MH; Husain N
    Cancer Genet; 2022 Nov; 268-269():55-63. PubMed ID: 36166960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.